• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据泵数据分析帕金森病中左旋多巴/卡比多巴肠凝胶的实际应用

Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data.

机构信息

Department of Neuroscience, Neurology, Uppsala University, Sweden.

出版信息

J Parkinsons Dis. 2020;10(4):1529-1534. doi: 10.3233/JPD-202114.

DOI:10.3233/JPD-202114
PMID:32651335
Abstract

BACKGROUND

Levodopa/carbidopa intestinal gel (LCIG) infusion is an efficacious treatment of motor and non-motor fluctuations in people with Parkinson's disease (PD). Real-life use of the treatment is not previously studied.

OBJECTIVE

The aims of the study were to explore the use of LCIG and to determine how extra doses of LCIG are used in daily life.

METHODS

Twenty-five PD patients with ongoing LCIG therapy were consecutively included. Pump data was retrieved from 30 days on average, by means of software, extracting the most recent pump events.

RESULTS

The daily duration of infusion was 15 hours on average, in 18 patients, whereas the remaining 7 patients used 24-hour infusion. Morning doses ranged from 38-190 mg levodopa, for patients who utilized this function. Median number of daily extra doses was 2.5 (range: 0-10.6) and median size of the extra dose was 24 mg (0-80 mg) levodopa. Median total daily levodopa intake with LCIG was 1201 mg (range: 417-2322 mg).

CONCLUSION

Retrieving pump data is possible and may be important for evaluating the at-home use of LCIG, to optimize the therapy. Adherence to treatment should be monitored, which is not technically difficult, at least in device-aided treatments for PD.

摘要

背景

左旋多巴/卡比多巴肠凝胶(LCIG)输注是治疗帕金森病(PD)患者运动和非运动波动的有效方法。该治疗方法在现实生活中的应用尚未得到研究。

目的

本研究旨在探讨 LCIG 的使用情况,并确定日常生活中 LCIG 的额外剂量如何使用。

方法

连续纳入 25 名正在接受 LCIG 治疗的 PD 患者。通过软件从平均 30 天的时间中检索泵数据,提取最近的泵事件。

结果

18 名患者的平均输注时间为 15 小时,而其余 7 名患者使用 24 小时输注。使用该功能的患者早晨剂量范围为 38-190mg 左旋多巴。每天额外剂量的中位数为 2.5(范围:0-10.6),额外剂量的中位数大小为 24mg(0-80mg)左旋多巴。LCIG 每日总左旋多巴摄入量中位数为 1201mg(范围:417-2322mg)。

结论

检索泵数据是可行的,对于评估 LCIG 的家庭使用情况、优化治疗可能很重要。至少在 PD 的设备辅助治疗中,应监测治疗的依从性,这在技术上并不困难。

相似文献

1
Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data.根据泵数据分析帕金森病中左旋多巴/卡比多巴肠凝胶的实际应用
J Parkinsons Dis. 2020;10(4):1529-1534. doi: 10.3233/JPD-202114.
2
Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.接受左旋多巴-卡比多巴肠凝胶输注治疗的帕金森病患者的多巴胺激动剂撤药综合征(DAWS)症状
Parkinsonism Relat Disord. 2015 Aug;21(8):968-71. doi: 10.1016/j.parkreldis.2015.05.018. Epub 2015 Jun 10.
3
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.左旋多巴-卡比多巴肠凝胶空肠输注与左旋多巴-卡比多巴片口服给药治疗日本晚期帕金森病患者的药代动力学、初步疗效及安全性比较
Clin Pharmacokinet. 2015 Sep;54(9):975-84. doi: 10.1007/s40262-015-0265-3.
4
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.左旋多巴-卡比多巴肠凝胶单药治疗:GLORIA 注册研究的人口统计学、疗效和安全性。
J Parkinsons Dis. 2019;9(3):531-541. doi: 10.3233/JPD-191605.
5
Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?奥匹卡朋与左旋多巴-卡比多巴肠凝胶输注系统:为医疗保健系统节省成本的未来之路?
J Parkinsons Dis. 2020;10(4):1535-1539. doi: 10.3233/JPD-202022.
6
The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.左旋多巴-卡比多巴肠凝胶输注长期治疗对晚期帕金森病运动并发症的影响:罗马尼亚多中心经验
J Neural Transm (Vienna). 2016 Apr;123(4):407-14. doi: 10.1007/s00702-015-1496-z. Epub 2015 Dec 23.
7
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.美国在门诊开始使用左旋多巴-卡比多巴肠凝胶治疗晚期帕金森病的现行做法。
Adv Ther. 2019 Sep;36(9):2233-2246. doi: 10.1007/s12325-019-01014-4. Epub 2019 Jul 5.
8
Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.十二指肠内左旋多巴-卡比多巴肠凝胶输注可改善晚期帕金森病的运动功能和生活质量。
J Clin Neurosci. 2016 Mar;25:41-5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14.
9
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.长期左旋多巴/卡比多巴肠凝胶治疗晚期帕金森病。
J Neurol. 2014 Mar;261(3):561-9. doi: 10.1007/s00415-013-7235-1. Epub 2014 Jan 30.
10
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.左旋多巴/卡比多巴肠凝胶输注治疗晚期帕金森病:7年经验
Eur J Neurol. 2014 Feb;21(2):312-8. doi: 10.1111/ene.12309. Epub 2013 Dec 7.

引用本文的文献

1
Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance.左旋多巴-恩他卡朋-卡比多巴肠凝胶输注治疗晚期帕金森病:真实世界经验与实践指南
Ther Adv Neurol Disord. 2022 Jun 26;15:17562864221108018. doi: 10.1177/17562864221108018. eCollection 2022.
2
Prodrug Therapies for Infectious and Neurodegenerative Diseases.用于感染性疾病和神经退行性疾病的前药疗法。
Pharmaceutics. 2022 Feb 26;14(3):518. doi: 10.3390/pharmaceutics14030518.
3
Initial Experience of the Levodopa-Entacapone-Carbidopa Intestinal Gel in Clinical Practice.
左旋多巴-恩他卡朋-卡比多巴肠凝胶在临床实践中的初步经验
J Pers Med. 2021 Mar 31;11(4):254. doi: 10.3390/jpm11040254.
4
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.福司列弗多巴/福卡多巴:帕金森病的一种新皮下治疗方法。
Ann Neurol. 2021 Jul;90(1):52-61. doi: 10.1002/ana.26073. Epub 2021 May 4.
5
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations.24 小时左旋多巴-卡比多巴肠凝胶:临床经验与实用建议。
CNS Drugs. 2021 Feb;35(2):137-149. doi: 10.1007/s40263-020-00782-w. Epub 2021 Feb 13.